?Host response and immunity to Yersinia pestis infection? Project Summary Type I interferons are expressed by eukaryotic cells upon intracellular invasion by microbial pathogens and they induce a potent anti-viral response. Yet during bacterial infection, expression of type I IFN often leads to a pathologic response that depletes populations of immune effector cells necessary to mediate clearance. Our laboratory has shown that type I IFN signaling contributes to neutrophil depletion during infection by Yersinia pestis, a Gram-negative bacterium that is the causative agent of the plague. Bubonic plague is a highly infectious vector borne disease that can be transmitted through the respiratory route and disseminated through the vasculature of its victims. Septicemic and pneumonic plagues involve the rapid development of an uncontrolled systemic inflammatory response that causes the clinical collapse of the patient, even with antibiotic treatment. These three forms of plague have been responsible for three major pandemics and still cause annual cases of human disease with a high mortality rate worldwide including a hotspot in the Southwestern United States. To date, little about the host responses that directly or indirectly contribute to the progression of plague. Such responses may present new strategies to approach the post- symptomatic treatment of plague and other acute inflammatory diseases. In this application, we propose to study interactions between phagocytic cells and Y. pestis that are responsible for inducing inflammatory responses that contribute to the progression of infection in a murine model. We have identified the broadly conserved Toll-like receptor 7 (TLR7) as activated during infection by wild type Y. pestis. Activation of TLR7 by Y. pestis triggers a non-canonical signaling pathway that induces the expression of type I IFN and its downstream IFN stimulated genes which subsequently interfere with the neutrophilic response and promote the progression of disease. In this project, we aim to understand the molecular signaling events of this novel pathway and their role during infection with Y. pestis. Our long term goal is to use the information gained from this program to better understand innate immune response to bacterial infection and develop host-targeted therapeutics that broadly protect from acutely inflammatory infectious diseases such as the infamous pneumonic plague.

Public Health Relevance

PI: Anderson, Deborah M Project Narrative Host response and immunity to Yersinia pestis infection Project Narrative The long term goal of our research is to better understand the human innate immune response to bacterial infection in order to develop therapeutics that target harmful host responses that are promoting disease. To achieve this, we are studying host interactions with Yersinia pestis, the causative agent of plague. Plague is a rapidly progressing lethal infection that is facilitated by the mammalian innate immune response. Our research has discovered a novel pathway for activating expression of type I IFN that contributes to the progression of plague. We hypothesize that inhibition of this pathway could be a novel therapeutic strategy for the treatment of pneumonic plague as well as other bacterial diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI129996-03
Application #
9685848
Study Section
Host Interactions with Bacterial Pathogens Study Section (HIBP)
Program Officer
Mukhopadhyay, Suman
Project Start
2017-05-08
Project End
2022-04-30
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
3
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Missouri-Columbia
Department
Veterinary Sciences
Type
Schools of Veterinary Medicine
DUNS #
153890272
City
Columbia
State
MO
Country
United States
Zip Code
65211
Dhariwala, Miqdad O; Olson, Rachel M; Anderson, Deborah M (2017) Induction of Type I Interferon through a Noncanonical Toll-Like Receptor 7 Pathway during Yersinia pestis Infection. Infect Immun 85: